Aligos Therapeutics, Inc.ALGSNASDAQ
LOADING
|||
R&D Expense Growth Recovery in Progress
Trending higher, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-3.79%
↓ 107% below average
Average (6y)
56.67%
Historical baseline
Range
High:321.17%
Low:-18.32%
Volatility
599.1%
High variability
| Period | Value |
|---|---|
| 2024 | -3.79% |
| 2023 | -14.15% |
| 2022 | -18.32% |
| 2021 | 30.37% |
| 2020 | 81.41% |
| 2019 | 321.17% |
| 2018 | 0.00% |